作者
Marwa S Mahdy, Ahmed F Azmy, Tarek Dishisha, Wafaa R Mohamed, Kawkab A Ahmed, Ahmed Hassan, Sahar El Aidy, Ahmed O El-Gendy
发表日期
2023/3/2
期刊
BMC microbiology
卷号
23
期号
1
页码范围
53
出版商
BioMed Central
简介
Background
Irinotecan is a chemotherapeutic agent used to treat a variety of tumors, including colorectal cancer (CRC). In the intestine, it is transformed into SN-38 by gut microbial enzymes, which is responsible for its toxicity during excretion.
Objective
Our study highlights the impact of Irinotecan on gut microbiota composition and the role of probiotics in limiting Irinotecan-associated diarrhea and suppressing gut bacterial β-glucuronidase enzymes.
Material and methods
To investigate the effect of Irinotecan on the gut microbiota composition, we applied 16S rRNA gene sequencing in three groups of stool samples from healthy individuals, colon cancer, and Irinotecan treated patients (n = 5/group). Furthermore, three Lactobacillus spp.; Lactiplantibacillus plantarum (L. plantarum), Lactobacillus acidophilus (L. acidophilus), Lacticaseibacillus rhamnosus (L. rhamnosus) were used in a single and mixed form to in-vitro …
引用总数